argenx Appoints Camilla Sylvest to Board of Directors
September 08 2022 - 2:10PM
September 8, 2022
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq:
ARGX), a global immunology company committed to improving the lives
of people suffering from severe autoimmune diseases, announced that
during the extraordinary general meeting of shareholders held today
at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive
director to its Board of Directors.
Mrs. Sylvest brings strong strategic and operational leadership
in the scaling of global commercial pharmaceutical organizations
with a specific focus on company culture and sustainability. The
voting result and all documents relating to the shareholders’
meeting will be available on the argenx website at
www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the
first-and-only approved neonatal Fc receptor (FcRn) blocker in the
U.S., Japan, and the EU. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit www.argenx.com and follow us
on LinkedIn, Twitter, and Instagram.
Media: Kelsey Kirk kkirk@argenx.com
Investors: Beth DelGiacco
bdelgiacco@argenx.com
Argen X (EU:ARGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Sep 2023 to Sep 2024